Compound Evidence File
#EC-2026-0302
Primobolan E Raw
Filed under Raw Materials. The bureau holds 120 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 27 Dec 2025 | 21 Jul 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 10.0 | 10.0 | 10.0 | 16 Dec 2025 | 15 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 10.0 | 9.9 | 10.0 | 14 Jan 2026 | 23 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 10.0 | 9.9 | 10.0 | 24 May 2026 | 11 Jul 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 4 | 9.9 | 9.9 | 10.0 | 6 May 2026 | 16 Jun 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 3 | 9.9 | 9.9 | 10.0 | 14 Jan 2026 | 3 Jul 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 3 Jul 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 7 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 2 Jun 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Jul 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 1 May 2026 | 14 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 20 Feb 2026 | 9 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 28 Feb 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 5 | 9.4 | 8.3 | 10.0 | 21 May 2026 | 21 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.8 | 8.2 | 10.0 | 21 May 2026 | 21 May 2026 |
| Top PeptideCASE #VI-2026-0721 | X | 2 | 8.8 | 8.5 | 9.0 | 17 Dec 2024 | 25 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 5 | 8.7 | 8.0 | 10.0 | 24 May 2026 | 24 May 2026 |
| UtherCASE #VI-2026-0902 | X | 1 | 8.7 | 8.7 | 8.7 | 20 Jun 2025 | 20 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.6 | 6.5 | 10.0 | 21 May 2026 | 21 May 2026 |
| Shandong Nuoweiou Medical Technology CoCASE #VI-2026-0076 | X | 1 | 8.2 | 8.2 | 8.2 | 24 Apr 2025 | 24 Apr 2025 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.0 | 7.5 | 8.3 | 21 May 2026 | 21 May 2026 |
| Yiwu Aozuo Trading CoCASE #VI-2026-0798 | X | 5 | 7.9 | 6.1 | 9.4 | 13 Jun 2025 | 20 May 2026 |
| Qing Li PeptideCASE #VI-2026-0469 | X | 14 | 7.4 | 5.5 | 9.1 | 20 Jun 2025 | 25 May 2026 |
| Eternal PeptidesCASE #VI-2026-0842 | X | 2 | 7.3 | 7.0 | 7.7 | 6 May 2025 | 21 May 2026 |
| Atomik LabzCASE #VI-2026-0327 | X | 3 | 6.9 | 5.5 | 8.4 | 27 Feb 2025 | 17 May 2026 |
| Shandong Shengyuan Peptide TechnologyCASE #VI-2026-0634 | X | 1 | 6.9 | 6.9 | 6.9 | 25 Apr 2025 | 25 Apr 2025 |
| Alpha-GenCASE #VI-2026-0905 | X | 2 | 6.8 | 5.1 | 8.5 | 20 Jun 2025 | 25 May 2026 |
| HazelCASE #VI-2026-0392 | X | 1 | 6.7 | 6.7 | 6.7 | 27 Feb 2025 | 27 Feb 2025 |
| Shanghai OuDaXin New Material Technology CenterCASE #VI-2026-0498 | E | 3 | 6.2 | 4.0 | 8.1 | 3 Jul 2025 | 23 May 2026 |
| Royal PeptidesCASE #VI-2026-0264 | X | 3 | 6.1 | 4.8 | 6.9 | 2 Jul 2025 | 26 Jan 2026 |
| SRY LabsCASE #VI-2026-0657 | X | 4 | 5.3 | 3.7 | 6.3 | 13 Feb 2025 | 20 May 2026 |
| Limitless Life NootropicsCASE #VI-2026-0980 | X | 2 | 4.5 | 2.8 | 6.3 | 27 Feb 2025 | 25 May 2026 |
| PurePEPSCASE #VI-2026-0552 | X | 1 | 3.8 | 3.8 | 3.8 | 25 Apr 2025 | 25 Apr 2025 |
Open any subject to view the batch-level evidence for Primobolan E Raw alone.